BidaskClub Upgrades HUTCHISON CHINA/S (HCM) to Buy
Other analysts have also recently issued research reports about the company. Zacks Investment Research cut HUTCHISON CHINA/S from a “hold” rating to a “sell” rating in a research report on Tuesday, March 26th. HSBC began coverage on HUTCHISON CHINA/S in a research report on Wednesday, March 27th. They issued a “buy” rating for the company. Finally, Deutsche Bank began coverage on HUTCHISON CHINA/S in a research report on Monday, March 4th. They issued a “buy” rating and a $26.82 price target for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $26.82.
Shares of HCM opened at $26.75 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.33 and a quick ratio of 4.19. The stock has a market capitalization of $3.56 billion, a price-to-earnings ratio of -46.93 and a beta of 1.04. HUTCHISON CHINA/S has a 52 week low of $20.83 and a 52 week high of $39.68.
About HUTCHISON CHINA/S
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Further Reading: Overbought
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.